We are a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases.
We currently have two Phase 2 clinical-stage product candidates. Laninamivir octanoate, which is being developed for the treatment of influenza A and B infections, recently completed a positive Phase 2 trial. We plan to advance our second lead candidate, Vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses, which is being developed to treat HRV infected patients with underlying respiratory illnesses, including moderate to severe asthma and chronic obstructive pulmonary disease, into a Phase 2b trial in the first quarter of 2015. In addition to these clinical development programs, we also have a compound BTA-C585, a fusion inhibitor, in IND-enabling studies for the treatment of respiratory syncytial virus infections in children and adults with cardiac and pulmonary disease. We plan to initiate a Phase 1 trial for BTA-C585 in mid-2015.
In addition to our research and development activities, we receive royalty revenue from two approved neuraminidase inhibitors: zanamivir, marketed worldwide as Relenza® by GlaxoSmithKline; and LANI, marketed in Japan as Inavir® by Daiichi-Sankyo.